FDA approves Ultragenyx gene therapy for glycogen storage disease type Ia on August 20, 2026 Accelerated Approval corn starch DTX401 gene therapy GENGLYCOS GlucoGene trial Glycogen Storage Disease GSDIa Ia requirements Ultragenyx United States Food and Drug Administration +